Most Read Articles
Roshini Claire Anthony, 6 days ago

The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.

Yesterday
Overall survival (OS) and head and neck cancer (HNC)-specific survival vary among HNC sites, according to a study. In particular, cigarette smoking is a prognostic factor of OS and HNC-specific survival in patients with cancer of the oral cavity and oropharynx, whereas alcohol consumption is a prognostic factor of both survival outcomes in patients with cancer of the larynx.
18 Sep 2017
The additional use of intermittent low-energy diet (LED) or daily meal replacements after a mean 10-percent weight loss and 1-year maintenance effectively maintains weight loss in obese patients with knee osteoarthritis for 3 years, according to a recent study.
2 days ago
Adiponectin, but not leptin, is significantly correlated with proteinuria and its severity in systemic lupus erythematosus (SLE) nephritis, reveals a new cross-sectional study.

Product Highlight - Keytruda

16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
  • Efficient: Significant efficacy and durable response. 41% ORR whose tumors expressed ≥50% PD-L1 and 84% of patients OR had ongoing responses1,2
  • Predictive: In NSCLC, testing for PD-L1 expression helps to identify patients most likely to respond and to develop a patient’s treatment algorithm1
  • Practical: Convenience dosing of 2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks3
  • Manageable Safety Profile: Most of the common adverse reactions were grade 1 or 24
  • PD-1 Blockade: Selectively targets PD-1 directly on the T-cell for the complete PD-1 pathway blockade of both PD-L1 and PD-L2 ligands4

References:
1. Supplement to: Garon EB et.al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl JMed. 2015; 372: 2018-2028
2. Garon EB et.al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl JMed. 2015; 372: 2018-2028
3. Keytruda pack insert LPC-MK 3475-IV-122015
4. Herbst RS et.al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016; 387 (10027): 1540-1550


Further and safety information is available in section 9d, New In This Issue and mims.com.
Full prescribing information is available upon request.
ONCO-1199329-0000 10/16

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.

Yesterday
Overall survival (OS) and head and neck cancer (HNC)-specific survival vary among HNC sites, according to a study. In particular, cigarette smoking is a prognostic factor of OS and HNC-specific survival in patients with cancer of the oral cavity and oropharynx, whereas alcohol consumption is a prognostic factor of both survival outcomes in patients with cancer of the larynx.
18 Sep 2017
The additional use of intermittent low-energy diet (LED) or daily meal replacements after a mean 10-percent weight loss and 1-year maintenance effectively maintains weight loss in obese patients with knee osteoarthritis for 3 years, according to a recent study.
2 days ago
Adiponectin, but not leptin, is significantly correlated with proteinuria and its severity in systemic lupus erythematosus (SLE) nephritis, reveals a new cross-sectional study.